Brought to you by 
HGS to use Dyax technology to screen for peptides
31 Oct 2001
Executive Summary
Dyax will apply its phage display method of drug discovery in a collaboration to identify and optimize leads for Human Genome Sciences' therapeutic targets. Dyax may also use its phage--viruses that attack bacteria and can be engineered to express peptides--to develop high-throughput screens for HGS and to purify its development candidates and drugs.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HGS to use Dyax technology to screen for peptides
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice